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a b s t r a c t 
During inﬂammation, several cytochrome P450 enzymes are downregulated. Recently it was shown that 
voriconazole metabolism is reduced during inﬂammation. Posaconazole, another triazole with broad- 
spectrum antifungal activity, is metabolised only to a limited extent by cytochrome P450 enzymes and 
to a wider extent by phase 2 enzyme systems. The aim of this study was to investigate posaconazole 
concentrations during inﬂammation. Patients aged ≥18 years receiving posaconazole prophylaxis or treat- 
ment for fungal infections were enrolled in a prospective observational study. Samples for posaconazole 
and C-reactive protein (CRP) concentrations were collected routinely for each patient. Longitudinal data 
analysis was performed to analyse the correlation between posaconazole serum trough concentrations 
and CRP values, corrected for potential factors that could inﬂuence the posaconazole concentration. Be- 
tween August 2015 and June 2017, 64 patients were recruited to this study. Data for 55 patients (511 
posaconazole samples) were included in the ﬁnal analysis. The overall median posaconazole concentra- 
tion was 1.8 mg/L [interquartile range (IQR) 1–2.9 mg/L, range 0.1–7.94 mg/L] and the overall median CRP 
concentration was 23.5 mg/L (IQR 5–75 mg/L, range 0–457 mg/L). Longitudinal data analysis showed that 
only the posaconazole daily dose (in mg/kg body weight) had a signiﬁcant inﬂuence on posaconazole 
concentration after correction for other factors ( P < 0.0 0 01). Posaconazole concentrations were not inﬂu- 
enced by CRP concentrations ( P = 0.77). Posaconazole concentrations are not inﬂuenced by inﬂammation, 
reﬂected by CRP concentration. Therefore, more frequent therapeutic drug monitoring of posaconazole 
during inﬂammation or after an infection subsides is not necessary. 
© 2019 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 



















Posaconazole, a broad-spectrum triazole antifungal, is widely
sed for prophylaxis of invasive aspergillosis [1] . Whilst posacona-
ole is the ﬁrst-line choice for prophylaxis of invasive aspergillosis,
oriconazole is recommended as ﬁrst-line treatment. Posaconazole
s used as a second choice for treatment of invasive aspergillosis
1] . ∗ Corresponding author. Tel.: + 31 50 361 4070; fax: + 31 50 361 4087. 
E-mail address: j.w.c.alffenaar@umcg.nl (J.-W. C. Alffenaar). 







924-8579/© 2019 The Author(s). Published by Elsevier B.V. This is an open access article
 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Until recently, it was diﬃcult to maintain therapeutic plasma
oncentrations of posaconazole administered as oral suspension
wing to inadequate absorption as well as drug–drug interactions
e.g. concomitant use of proton pump inhibitors) and insuﬃcient
ood intake [2] . These issues led to substantial intra- and inter-
ndividual patient variability in the pharmacokinetics of posacona-
ole, and adequate trough concentrations were not easily achieved
3] . After these studies, there was a general consensus to routinely
erform posaconazole therapeutic drug monitoring (TDM). [4–9] .
he introduction of the new modiﬁed-release tablet and an intra-
enous (i.v.) formulation have further improved drug absorption,
nd thereby exposure, compared with the previously used suspen-
ion [10,11] . under the CC BY-NC-ND license. 














































































































ﬁ  As the use of posaconazole is becoming more widespread, other
factors inﬂuencing the pharmacokinetics of posaconazole should
be investigated, e.g. the presence of inﬂammation. Recently it has
been shown that inﬂammation, expressed by C-reactive protein
(CRP) concentration, affects the serum concentrations of voricona-
zole, which can be explained by downregulation of cytochrome
P450 isoenzymes [12–14] . Posaconazole, however, is metabolised
only to a limited extent by cytochrome P450 enzymes [15,16] and
is mostly metabolised through phase 2 enzyme systems using uri-
dine diphosphate-glucuronosyltransferase (UGT) enzyme pathways
[17] . UGT enzymes are inhibited during inﬂammation, thus there is
also a chance of posaconazole concentrations being affected [18] .
However, as cytochrome P450 isoenzymes are not involved to a
large extent, it is likely that posaconazole clearance is not inﬂu-
enced by inﬂammation expressed by elevated CRP concentrations.
None the less, there are no published data to support the hypoth-
esis that posaconazole exposure is not inﬂuenced by inﬂammation
expressed by CRP concentrations. 
Therefore, the objective of this study was to determine whether
posaconazole drug exposure is inﬂuenced during inﬂammation. 
2. Materials and methods 
2.1. Study design 
A prospective, observational study was performed at the Uni-
versity Medical Center Groningen (UMCG), Groningen, the Nether-
lands. Patients aged ≥18 years who received posaconazole for
treatment or (primary and secondary) prophylaxis of fungal infec-
tions were eligible to enter this study. Patients were excluded if
they concomitantly used a strong cytochrome P450 inhibitor or in-
ducer. 
Both for prophylaxis and invasive aspergillosis the loading dose
on Day 1 was 300 mg twice daily and the daily dose was 300 mg
once daily [1] . Samples used for routine TDM of posaconazole as
well as posaconazole concentrations that were measured from dis-
carded blood (taken for other clinical reasons) were included in the
analysis. Discarded blood was collected from all hospitalised pa-
tients during their hospital stay (4–5 days). Only conﬁrmed trough
concentrations were included in the analysis. Steady-state was con-
sidered to have been achieved by Day 6, and all levels of sam-
ples that were taken before Day 6 were excluded from the ﬁnal
data analysis [19] . During the study period, patients received oral
(modiﬁed-release tablets) or i.v. posaconazole. Posaconazole dos-
ing was done according to Infectious Diseases Society of America
(IDSA) guidelines [1] . 
2.2. Ethics 
Treatment with posaconazole and the use of TDM for posacona-
zole were part of routine care and were neither initiated nor al-
tered for study purposes. If the posaconazole concentration was
low, the attending hospital pharmacist provided the attending
physician with a dosage advice. Posaconazole concentrations from
discarded blood samples were measured afterwards. This study
was evaluated by the Medical Ethics Committee of UMCG. Writ-
ten Informed consent was obtained from each patient. The study
was registered at ClinicalTrials.gov under ID no. NCT02492802. 
2.3. Posaconazole concentrations 
Posaconazole plasma concentrations were measured using a
validated liquid chromatography–tandem mass spectrometry assay
with a lower limit of quantiﬁcation of 0.1 mg/L [20] . This assay was
externally conﬁrmed by an international proﬁciency testing pro-
gramme [21] . .4. Data collection 
Data were documented in a case report form and included
atient age, sex, weight, height, underlying disease, posaconazole
ose (mg/kg/day), time and route of administration, and potentially
nteracting cytochrome P450 co-medications. 
To assess the level of inﬂammation, CRP concentrations were
ollected from each patient’s medical record. Besides CRP, rou-
ine laboratory parameters, alkaline phosphatase (ALP), alanine
minotransferase (ALT), aspartate aminotransferase (AST), gamma-
lutamyl transferase ( γ -GT), total bilirubin and albumin were col-
ected from each patient’s medical record. 
.5. Statistical analysis 
Continuous variables were summarised as the median and in-
erquartile range (IQR), and nominal variables as the frequency and
ercentage. Longitudinal data on the posaconazole concentration
as analysed using a linear mixed model. 
As the data were not normally distributed, a log transformation
as performed on posaconazole concentrations. To determine the
ifferences in concentrations between patients, a random additive
ffect was used. In addition, a ﬁrst-order autoregressive correlation
as used to correct for differences in intervals between observa-
ions. The Wald type III test was used to assess the inﬂuence of in-
ammation on posaconazole concentration. The test was corrected
or age, sex, posaconazole dose, route of administration, ALP, ALT,
ST, γ -GT and total bilirubin. A second test was performed and
dditionally corrected for albumin. 
Statistical analysis was performed using SAS 9.3 (SAS Institute
nc., Cary, NC). A P -value of < 0.05 was considered statistically sig-
iﬁcant. 
. Results 
Between August 2015 and June 2017, a total of 64 patients were
nrolled in this study, of which 9 were eliminated from the ﬁnal
nalysis (2 because no CRP was measured for these patients and 7
ecause the measured posaconazole samples were not collected at
teady-state). Thus, 55 patients with a median age of 62 years (IQR
6–69 years) were included for ﬁnal analysis of the data. Patient
haracteristics are presented in Table 1 . 
In total, 511 posaconazole trough samples with an overall me-
ian concentration of 1.8 mg/L (IQR 1–2.9 mg/L, range 0.1–7.94
g/L) were obtained, and a median of seven samples (IQR 3–12,
ange 1–28) were collected per patient. Of the 511 posaconazole
amples, 217 were measured as part of routine TDM and a dosage
hange was recommended by the clinical pharmacist for 53 (24.4%)
f these. The other 294 samples were discarded blood samples
rom routine laboratory analyses. The number of CRP concentra-
ions obtained was 386, with an overall median CRP concentration
f 23.5 mg/L (IQR 5–75 mg/L, range 0–457 mg/L). 
Two patients received interacting co-medication. One patient
eceived omeprazole while also receiving posaconazole suspension,
nd another patient had received rifampicin < 2 weeks before the
tart of posaconazole treatment. As the interacting medications
ould have affected drug concentrations, the samples taken during
reatment and 1 week after treatment with interacting medications
ere eliminated from the ﬁnal analysis. 
Fig. 1 shows a scatterplot with posaconazole trough concentra-
ions (mg/L) divided by daily dose (mg/kg body weight) and CRP
alues (mg/L) to visually describe the correlation between these
ariables. It can be seen that the CRP concentration does not ap-
ear to affect the dose concentration ratio. 
A longitudinal data analysis was performed to conﬁrm these
ndings. The posaconazole concentrations were not normally
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Table 1 
Characteristics of patients included in the study ( n = 55). 
Characteristic No. (%) of patients or median (IQR) 
Male sex 33 (60) 
Age (years) 62 (56–69) 
Weight (kg) 80 (71–86) 
Height (cm) 176 (168–185) 
BMI (kg/m 2 ) 25.7 (23.4–26.8) 
Underlying conditions 
AML 35 (64) 
MDS 8 (15) 
Other a 12 (22) 
Stem cell transplant 
Allogeneic 22 (40) 
Autologous 2 (4) 
No transplant 31 (56) 
Posaconazole treatment 
Therapeutic issue 
Prophylaxis 40 (73) 
Treatment 15 (27) 
Route of administration 
Oral 50 (91) 
Intravenous and oral 5 (9) 
Daily dose (mg/kg body weight) 3.75 (3.4–4.9) 
IQR, interquartile range; BMI, body mass index; AML, acute myeloid 
leukaemia; MDS, myelodysplastic syndrome. 
a Other includes X-linked gammaglobulinaemia, T-cell prolymphocytic 
leukaemia, follicular lymphoma, chronic myelomonocytic leukaemia, Burkitt’s 
lymphoma, blastic plasmacytoid dendritic cell neoplasm, enteropathy- 
associated T-cell lymphoma type 2, systemic mastocytosis, primary cutaneous 
T-cell lymphoma, aplastic anaemia, primary myeloﬁbrosis and acute promye- 
locytic leukaemia. 
Fig. 1. Scatterplot showing posaconazole concentration divided by daily dose 










































































w  istributed, thus a log transformation was performed. This anal-
sis showed that the posaconazole daily dose (mg/kg) had a sig-
iﬁcant inﬂuence on posaconazole concentration ( P < 0.0 0 01) and
hat posaconazole concentrations were not signiﬁcantly inﬂuenced
y CRP concentrations ( P = 0.77) after correction for other potential
onfounding factors (i.e. sex, age, underlying disease, posaconazole
ose, ALP, AST, ALT, γ -GT, total bilirubin and CRP, and excluding
lbumin). 
To conﬁrm the results, a post-hoc analysis was performed to
etermine whether a clinically relevant change of CRP would re-ult in a change of posaconazole concentration. Based on the esti-
ated standard error and the degrees of freedom for CRP associ-
tion in the analysis, the t -distribution was used to calculate the
nticipated power if the association would be truly larger than the
linical association. We aimed to see whether a change of 10 units
f CRP would result in an absolute change of 0.3 mg/L posacona-
ole concentration. The association of CRP with posaconazole
oncentration was determined through multiple regression (log-
ransformed posaconazole concentrations were regressed on CRP
oncentrations). For this reason, the previously mentioned clini-
ally relevant association was translated to a percentage change of
4.78% ( = 100% ×0.3/2.03) with respect to the average posacona-
ole concentration. This means a percentage change of posacona-
ole concentration of ca. 1.5% for every unit change in CRP. The
tandard error per unit change CRP was estimated at 0.3825% with
12 degrees of freedom. This results in an estimated post-hoc
ower of 97.4%. 
The second longitudinal analysis was corrected for all previ-
usly mentioned variables, including albumin ( n = 184). This anal-
sis included less samples as albumin was not routinely measured
or all patients. There was still a signiﬁcant interaction between
he daily dose (mg/kg body weight) and posaconazole concentra-
ion ( P = 0.04). In addition, the albumin level had a signiﬁcant in-
uence on posaconazole concentration ( P = 0.0012). At lower al-
umin concentrations, lower posaconazole trough concentrations 
ere observed and CRP still did not have an effect ( P = 0.21). 
. Discussion 
This study investigated the effect of inﬂammation expressed by
RP values on posaconazole concentrations. CRP was chosen as a
arker of inﬂammation as it is routinely measured in clinical prac-
ice and it has been previously shown that high CRP concentrations
re associated with high voriconazole concentrations [14] . The re-
ults of this study showed that posaconazole exposure was not in-
uenced by CRP concentrations ( P > 0.05) and only posaconazole
aily dose (mg/kg body weight) had a signiﬁcant effect on drug
oncentrations. An additional power analysis conﬁrmed that these
esults have a post-hoc power of 97.4%. The CRP range is compara-
le with the range reported in the voriconazole study by Veringa
t al., where it was shown that in the case of a CRP increase to 200
g/L, voriconazole concentration is expected to increase approxi-
ately to 4 mg/L [14] . In the current study with posaconazole, a
linically signiﬁcant effect of CRP on posaconazole concentrations
as not observed. 
On the other hand, we are making assumptions over only a
art of posaconazole metabolism as it is eliminated mostly through
aecal excretion and to a lesser extent through urinary excretion.
ost of the excreted drug is shown to be unchanged in the fae-
es [22] . Moreover, as mentioned before, the majority of remaining
osaconazole is metabolised through phase 2 enzyme systems us-
ng UGT enzyme pathways (mostly UGT1A4) [17] . It is also known
hat enzyme UGT1A4, UGT2B7 and UGT2B4 mRNA levels are inﬂu-
nced by inﬂammation expressed through interleukin-1 β (IL-1 β)
RNA, tumour necrosis factor- β and IL-6 [18,23] . As CRP is pro-
uced by IL-6 stimulation, we can assume that the metabolism of
GT is taken into consideration [24] . 
The median CRP concentration was 23.5 mg/L and the major-
ty of included patients received posaconazole for prophylaxis. We
aw that according to the severity of inﬂammation, expressed by
RP concentration, there is no indication that inﬂammation inﬂu-
nces posaconazole metabolism. A possible limitation to this study
s that the majority of patients had a low CRP value and thus a low
rade of inﬂammation. 
In the secondary longitudinal analysis it was observed that
ith decreasing albumin concentrations, lower posaconazole












































































































 concentrations were observed. This effect could be caused by the
high protein binding of posaconazole ( > 98%, mainly to albumin)
[19] . The free fraction of highly protein-bound drugs can be signif-
icantly affected by small changes in protein binding [25,26] . Ide-
ally, the free concentration of a drug is measured, since total blood
concentrations are affected by hypoalbuminaemia [26] . However,
in clinical practice it is an analytical challenge to measure free
drug concentrations for posaconazole as the high protein binding
results in very low free concentrations of the drug. These low con-
centrations are far below the lower limits of quantiﬁcation of the
currently available assays [20,27,28] . As the current study was de-
signed to analyse the effect of inﬂammation on total posacona-
zole concentrations and a limited number of albumin concentra-
tions were included in this analysis, a separate study should be
performed collecting detailed information on free drug concentra-
tions and plasma proteins to further explore this observation. 
The discussion whether to perform routine posaconazole TDM
for modiﬁed-release tablets is ongoing. A study in lung trans-
plant recipients who received modiﬁed-release tablets showed that
posaconazole plasma concentrations are variable [29] . The current
study contributes to this debate by eliminating the possible effect
of inﬂammation, expressed by CRP concentration, as a potential
source of pharmacokinetic variability of posaconazole. 
In conclusion, the results of this study show that posaconazole
levels are not inﬂuenced by inﬂammation expressed by CRP con-
centrations. Therefore, more frequent TDM of posaconazole during
inﬂammation or after an infection subsides appears unnecessary. 
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